(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
A rare whale is having an encouraging season for births. Scientists warn it might still go extinct - 2Journalists killed by Israeli strike in southern Lebanon
- 3Lily Allen 2026 'West End Girl' Tour: How to get tickets, prices, presale info and more
- 4Israel’s mixed messaging on Christmas draws controversy
- 5Watch Rocket Lab launch Japanese technology-demonstrating satellite to orbit tonight
- What we know about Jonathan Ross, the ICE agent who shot and killed Renee Nicole Good in Minneapolis
- A 'Stranger Things' documentary covering the final season is on its way: Watch the trailer
- NASA counts down for first crewed lunar mission in half a century
- How the Iran war may affect your money and bills
- Current Chateaus: Advancement and Style
- They want better health care — so they're turning to crypto startups
- The most effective method to Promoter for Cutthroat Medical attendant Compensations in Your Medical services Office
- Tzrifin base exhibition reveals Hamas and Hezbollah arms, showing structure behind attacks
- 5 Cell phones of the Year
